Printer Friendly

Forum Alert: BioSante Pharmaceuticals, Inc. will Present at the Informed Investors Biotechnology & Healthcare Investor Forum at The Hyatt Regency in San Francisco on Wednesday, December 7, 2005, 10:50 am PST.

LINCOLNSHIRE, Ill. -- BioSante Pharmaceuticals, Inc. (AMEX: BPA) will present at the following forum:

What: Informed Investors Biotechnology & Healthcare Investor Forum in San Francisco

When: December 7, 2005 @ 10:50 AM Pacific Standard Time

Sponsors: Barron's, The Wall Street Journal and Business Wire

Keynote Presentations: John McCamant, Editor of The Medical Technology Stock Letter, Adam Noah, Ph.D., Vice President, Biotechnology Equity Research, Merriman Curhan Ford & Co.

Forum Highlights Include: Networking session and Industry Panel Discussion at the conclusion of the presentations

Where: The Hyatt Regency Hotel, 5 Embarcadero Center, San Francisco, CA 94111

How to attend: Pre-registration is necessary. To register, contact Cary Loeser, cloeser@wilink.com, or 804-327-3407. You may also call Customer Service at 888-301-6618, or register at the following link: http://www.investorcalendar.com/IIF/CustomEvent/90563/index.asp

If you are unable to attend the live event, the forum will be archived and available via webcast at http://www.investorcalendar.com/IIF/CustomEvent/90563/index.asp

Contact: Phillip Donenberg, Chief Financial Officer, donenber@biosantepharma.com , (847)478-0500

BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone. BioSante's lead products include Bio-E-Gel(TM) (bioidentical estradiol gel) for the treatment of women with menopausal symptoms, and LibiGel(TM) (bioidentical testosterone gel) for the treatment of female sexual dysfunction (FSD). The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion. The company also is developing its calcium phosphate nanotechnology (CAP) for novel vaccines, including biodefense vaccines for toxins such as anthrax and ricin, and drug delivery systems.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1CANA
Date:Nov 30, 2005
Words:277
Previous Article:Toshiba Expands Cardiac CT Training Program for Aquilion 64 Customers; Expansion Aimed at Meeting Industry Demand for Practical Training Using...
Next Article:A Record of the Topics Discussed at the 8th Real Estate & Investment Forum Which Was Attended by over 500 Key Real Estate Players.
Topics:


Related Articles
Investors to Hear from over 10 Companies at Biotechnology & Healthcare Investor Forum in San Francisco on December 7.
Forum Alert: Symbollon Pharmaceuticals, Inc. will Present at the Informed Investors Biotechnology & Healthcare Investor Forum at The Hyatt Regency in...
Forum Alert: Aeolus Pharmaceuticals Inc. will Present at the Informed Investors Biotechnology & Healthcare Investor Forum at The Hyatt Regency in San...
Forum Alert: Antares Pharma Inc. will Present at the Informed Investors Biotechnology & Healthcare Investor Forum at The Hyatt Regency in San...
Forum Alert: Ceragenix Pharmaceuticals, Inc. will Present at the Informed Investors Biotechnology & Healthcare Investor Forum at The Hyatt Regency in...
BioSante Pharmaceuticals to Present at Informed Investors Biotechnology and Healthcare Forum.
Calendar.
Calendar.
Calendar.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters